Výnosy R/R společnosti Edesa Biotech
Jaká je hodnota metriky Výnosy R/R společnosti Edesa Biotech?
Hodnota metriky Výnosy R/R společnosti Edesa Biotech, Inc. je N/A
Jaká je definice metriky Výnosy R/R?
Roční růst tržeb za poslední 3 roky (Revenue Y/Y) představuje růst tržeb z roku na rok zprůměrovaný za poslední 3 roky.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
Čemu se věnuje společnost Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.